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ABSTRACT 
Mesenchymal stem cells have been proven to be potentially effective in the 
treatment of a large variety of diseases, including neurodegenerative disorders. 
Of these, cerebellar ataxia is a group of disorders characterized by the 
degeneration of the cerebellum, particularly the Purkinje cells, responsible for 
motor coordination and control of the motor functions. To analyze the possibility 
of using bone marrow-derived mesenchymal stem cells in treating ataxia, we 
transplanted these cells in the cerebellum of newborn Lurcher mutant mice, a 
very aggressive mouse model characterized by the selective early post-natal 
death of Purkinje cells in the cerebellum. Two months after the surgical 
procedure, the treated mice presented significant improvements in the motor 
behavior tests performed. Histological analysis of the cerebellum indicated that 
the donor cells had migrated throughout the cerebellum, as well as a significant 
increase in the number of Purkinje cells. Many grafted stem cells were located 
adjacent to the Purkinje cell layer, and expressed BDNF, NT-3 or GDNF, 
neurotrophic factors implicated in Purkinje cell survival. Also, a small 
percentage of the grafted stem cells had fused with Purkinje cells. Thus, we 
have shown that mesenchymal stem cells are capable of integrating into the 
central nervous system, migrate towards the areas where neurodegenerative 
processes are occurring, and rescue the degenerating cells through cell trophic 
effects. This is an adequate and feasible model that could be translated into a 
therapeutic approach for clinical assays in neurodegenerative diseases.  
KEY WORDS: Mesenchymal stem cells, Lurcher mouse, cerebellar ataxia, 
neurotrophic effect, Purkinje cells, bone marrow, cell fusion 
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INTRODUCTION 
Bone marrow transplantation has been demonstrated to be a feasible 
therapeutic approach for the treatment of a variety of diseases, such as 
leukemia and lymphoma. Also, many studies have shown that stem cells in the 
bone marrow, particularly mesenchymal stem cells, are potentially a useful tool 
for the rescue and protection of target cells in degenerative disorders, including 
neurodegenerative diseases. In this type of diseases, the rescue has been 
proven to occur for several reasons. For example, several studies have 
demonstrated that mesenchymal stem cells are capable of releasing 
neurotrophic factors such as NGF, BDNF and NT-3, among others (Chen Q. et 
al 2005, Caplan A.I. et al 2006, Rodrigues-Hell R.C. et al 2009), which protect 
the degenerating cells and increase their chance for survival. Also, stem cells 
can fuse with the host‟s degenerating neurons (Alvarez-Dolado M. et al 2003, 
Weimann J.M. et al 2003a and 2003b, Johansson C.B. et al 2008). In general 
terms, this process occurs at a very low frequency, thus was initially considered 
to be therapeutically inefficient (Wagers A.J. et al 2002). However, a recent 
publication has shown that under certain circumstances, the fusion process may 
occur more frequently (Johansson C.B. et al 2008), reconsidering this process 
as a feasible therapeutic method. Thus, the objective of this study was to 
analyze the processes by which bone marrow-derived mesenchymal stem cells 
rescue neurons in a neurodegenerative mouse model of cerebellar ataxia. 
To this end, we used the Lurcher mutant mouse. This mouse model, first 
described in 1960 by R.J.S. Philips, is a spontaneous semidominant mutation 
characterized by a wobbly ataxia due to the selective postnatal degeneration of 
Purkinje cells as well as the majority of their primary afferents, granule cells and 
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olivary neurons (Phillips R.J.S. et al 1960). The cause for this degeneration is 
due to a mutation of the δ2 glutamate receptor (GluRδ2) (Zuo J. et al, 1997). 
Homozygous animals die around birth, whereas heterozygous animals are 
viable, and have been extensively used in studies of neurodegeneration and 
survival. Heterozygotes begin to present abnormalities in the Purkinje cells as 
soon as 3-4 days after birth. These cells, due to the mutation in the glutamate 
receptor, present a constitutive cationic current, which ultimately causes their 
death. The process by which this cell death occurs is not well understood, 
where autophagy, necrosis and apoptosis processes have been described. By 3 
months of age, virtually all Purkinje cells, and the vast majority of granule cells 
and olivary neurons, have disappeared. For a review on the Lurcher mice, see 
Vogel et al, 2007.  
In our approach, we transplanted either whole bone marrow or bone marrow-
derived mesenchymal stem cells into the cerebellum of newborn Lurcher mice, 
before the neurodegeneration processes commence. Several authors have 
used this strain as a mouse model of neurodegeneration, usually transplanting 
neural progenitors or adult Purkinje cells (Tomey D.A. et al 1993, Dumesnil-
Bousez N. et al 1993a and 1993b, Heckroth J.A. et al 1998, Cendelin J. et al 
2009), however this is the first report to use bone marrow-derived stem cells in 
this model. The mice, once they reached a certain age, were submitted to 
behavior tests on the rotarod to analyze their possible motor function recovery 
compared to sham operated and non-grafted heterozygous Lurcher mice. After 
the tests, the mice were sacrificed and their brain analyzed for the detection of 
the grafted cells, as well as to study the processes induced by these cells in the 
cerebellum. 
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MATERIALS AND METHODS 
1. Animals 
All the experiments with animals have been performed in compliance with the 
Spanish and European Union laws on animal care in experimentation 
(Council Directive 86/609/EEC), and have been analyzed and approved by 
the Animal Experimentation Committee of our university. Green fluorescent 
protein (GFP) transgenic mice and Lurcher mutant mice were bred and 
maintained in our animal facilities. GFP mice ubiquitously express the green 
fluorescent protein under the control of the β-actin promoter (Okabe M. et al 
1997).  
 
2. Bone Marrow Isolation and Mesenchymal Stem Cell Culture 
Unless stated otherwise, all the materials and substances were purchased 
from Sigma-Aldrich. Femurs were dissected from 6- to 8-week old GFP mice, 
sacrificed by cervical dislocation. Bone marrow was extracted, and single-cell 
suspensions were obtained by mechanical dissociation. In the case of whole 
bone marrow (BM) transplantation, the cells were re-suspended in D-MEM 
and taken to the surgery room. In the case of mesenchymal stem cell (MSC) 
culture, the bone marrow suspension was washed and centrifuged, and the 
pellet was then re-suspended in D-MEM (Invitrogen) supplemented with 15% 
FBS (Biochrom AG, Berlin), 100 U/ml penicillin/ streptomycin, 1 mM sodium 
pyruvate, 1% non-essential amino acids, and 1 ng/ml FGF2. These cells 
were placed in culture flasks and the plastic-adherent population was isolated 
and allowed to proliferate for 3-4 weeks, changing the media every 2-3 days. 
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Approximately every 5-7 days, the cells were trypsinized with trypsin/EDTA 
0.25% and replated in 75 cm2 flasks. After 3-4 weeks, all the cells in culture 
expressed CD90 and CD44 and were negative for CD34 and CD45, 
confirming that the cell population was mainly composed of mesenchymal 
stem cells (data not shown). 
 
3. Cell Transplantation 
Mesenchymal stem cells were injected into the cerebellum of newborn 
Lurcher mice. To this end, the mice were cryoanesthesized before the 
surgical procedure. With a glass capillary attached to a Hamilton syringe 
(Hamilton, Reno, Nevada), either 500,000 BM or 250,000 MSC cells in 2 μl of 
D-MEM were unilaterally injected into the cerebellum, located 2.5 mm caudal 
to Lambda (beginning at the midline), 0.5 mm deep. The treated mice were 
compared to control Lurcher mutants which were not submitted to the 
transplantation process, and to sham controls, which were injected with 2 μl 
of D-MEM.  
After the injection, the mice were reanimated and quickly placed with their 
mothers to avoid rejection.   
 
4. Rotarod Assays 
The rotarod test was performed on an 8500 Rota-rod (Letica Scientific 
Instruments, Barcelona, Spain). The lane is 500 mm wide, and the rod has a 
diameter of 30 mm. First, once the mice reached three weeks of age and the 
symptomatic mice could be detected, they were trained daily for one week on 
the rotarod. Afterwards, they were analyzed on a weekly basis, taking note of 
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the time they spent walking on the rotating rod at a constant speed of 4 rpm. 
Also, their maximum walking speed was noted, by increasing the speed at a 
constant rate of 4 to 40 rpm in a 1-minute interval until the animal fell from the 
rotarod. The mice were placed on the rotarod 10 times for each test, and the 
average value was calculated. These tests were performed for a total of 5 
weeks, until the mice reached the age of 8 weeks. 
 
5. Tissue Fixation and Immunohistochemistry 
After the 5-week rotarod tests, the mice were anesthetized with isofluorane 
and fixed by intra-cardiac perfusion with 4% filtered paraformaldehyde (PFA) 
in phosphate buffer (pH 7.4). The brain was carefully excised and kept in 4% 
PFA overnight. After fixation, the samples were cryoprotected by increasing 
concentrations of sucrose (up to 30%) and finally embedded in Neg-50 
Frozen Section Medium (Richard-Allan Scientific, Kalamazoo, Michigan), 
frozen, and stored at -20ºC. Thirty micrometer sagittal sections were 
obtained using a Microm HM525 cryostat and mounted on slides.  
The sections were first incubated at room temperature in 10% goat serum, 
5% bovine albumin, 0.25% triton and PBS to permeate the tissue and block 
non-specific binding. Afterwards, the sections were incubated overnight at 
room temperature with the primary antibody, diluted in blocking solution (10% 
goat serum, 5% bovine albumin and PBS). The following primary antibodies 
were used: rabbit anti-calbindin (1:3000, Swiss Antibodies, Bellinzona, 
Switzerland), mouse anti-GFP (1:200, Molecular Probes, Eugene, OR), rabbit 
anti-GDNF (1:100, Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-
BDNF (1:200, Santa Cruz Biotechnology, Santa Cruz, CA), sheep anti-
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neurotrophin-4/5 (NT-4/5, 1:100, Chemicon/Millipore, Billerica, MA), sheep 
anti-nerve growth factor (NGF, 1:500, Chemicon/Millipore, Billerica, MA) and 
sheep anti-neurotrophin-3 (NT-3, 1:100, Chemicon/Millipore, Billerica, MA). 
The following day, the sections were incubated with the secondary antibody. 
For GFP staining, we used anti-mouse Alexa Green (1:500, Molecular 
Probes), and for the other antibodies biotinylated secondary antibodies were 
used (1:200, Vector Laboratories, Burmingham, California) followed by an 
incubation with streptavidin conjugated with Cy3 (1:500). DAPI (Molecular 
Probes) was used to stain nuclei. In some cases, the secondary antibody 
used was conjugated with peroxidase for DAB staining (Applichem, 
Germany), and the tissue counterstained with cresyl violet (Acros Organics, 
Belgium). Histological samples were observed under a fluorescence 
microscope (Leica DMR, Leica Microsystems) and micrographs taken with a 
confocal microscope (Leica DMR). 
 
6. Cell Count 
To count the number of Purkinje cells and grafted cells, 
immunohistochemistry was performed for calbindin and GFP, respectively. 
Then, the positive cells in the 10 center-most sections and the average 
number per section was calculated in the control and experimental cerebella. 
This was also performed to count the number of fused cells, as well as the 
grafted cells expressing neurotrophic factors. 
    
7. Post-transplant Cerebellar Culture and Immunocytochemistry 
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After the MSC transplant and rotarod assay, 3 mice from 3 different 
experiments were sacrificed and brain extracted. The cerebellum was 
isolated and placed in a culture dish with D-MEM, minced into small pieces 
and mechanically disaggregated. The tissue was then centrifuged and the 
resulting pellet was re-suspended in standard MSC culture medium 
(described previously) and placed in several 35 mm treated culture dishes. 
After 5 days of culture, the cultures were fixed with 4% paraformaldehyde and 
stained for GFP and calbindin. The staining protocol used was similar to the 
tissue staining commented previously, only 0.025% Triton was used to 
permeabilize the cells. The samples were visualized under the fluorescence 
microscope. 
 
8. Statistical Analysis 
Statistical significance between control and experimental groups were 
calculated with SPSS v11.0 software, using ANOVA and the non-parametric 
Mann Whitney test. 
 
RESULTS 
1. MSC-treated mice significantly improve in the behavior tests 
A total of 38 lurcher mutant mice were used, distributed in 15 non-treated 
controls, 8 shams, 5 BM-treated and 10 MSC-treated mice. The experimental 
approach consisted in transplanting newborn Lurcher mice with either D-MEM 
(for shams), recently extracted bone marrow (BM-treated mice), or cultured 
mesenchymal stem cells (MSC-treated mice). Once the mice reached the age 
of 3 weeks, the symptomatic mice were isolated and trained in the rotarod at 
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both a constant speed of 4 rpm and at increasing speeds. This was 
performed during a total of 6 weeks, in which during the first week the mice 
were placed daily as training for the weekly tests performed afterwards. After 
the 5-week tests, the mice were sacrificed and brains extracted and 
processed for histological analysis (See Figure 1A for a chronogram of the 
experimental procedure). 
During the first runs, the mice had many difficulties to walk on the rotarod, 
where in many cases they would just hold on to the rod until they fell, as 
previously seen by other authors (Hilber P. et al 2001). However, after the 
training period, the mice were capable of walking on the rod for several 
seconds in a similar fashion as a wildtype mouse would. The results of the 
rotarod tests are shown in Figure 1B. When the rotarod was placed at a 
constant speed of 4 rpm, the control mice were capable of walking, on 
average, for 12-20 seconds before falling (n = 10). Similar values were 
obtained with sham controls, which walked for 14-19 seconds (n = 8). These 
values were very stable throughout the weeks, with no evident improvement 
throughout time. As for the treated mice, the BM mice obtained values that 
were above the control and sham mice, though not significant (average 15-45 
seconds, n = 5). On the other hand, MSC mice were capable of walking on 
average for 60-100 seconds, almost 5 times longer than the controls (n = 10). 
Both experimental groups seemed to obtain increasingly higher scores with 
each passing week, which was not observed in the controls. The average 
deviations of the charts, particularly in the MSC group, are very large, due to 
the variability of each mouse. For example, one of the MSC mice was 
capable of walking for over 400 seconds. Despite the variability, it was clear 
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that the MSC-treated mice obtained significantly better results than the 
control mice in this test (p < 0.05, p < 0.001 with Mann Whitney test). 
As for the rotarod test at increasing speeds, on average, the control mice 
were capable of walking until reaching speeds of 9-12 rpm, while the sham 
averaged 9 rpm. As for the treated mice, the BM mice had scores that were 
similar to the controls (9-13 rpm) while the MSC reached slightly higher 
scores (12-14 rpm). Except for one of the weeks, the MSC-treated mice 
presented significantly higher values compared to the controls (p < 0.05, p < 
0.001 with Mann Whitney).  
Thus, MSC mice were capable of walking on the rotarod for much longer 
periods of time, indicating a significant improvement in the motor coordination 
of these mice.  
 
2. After 1 month, mesenchymal stem cells have migrated throughout the 
cerebellum using the white matter 
Several non-symptomatic treated mice were sacrificed at 1 month of age, to 
confirm that the injected cells survived the surgical procedure (n=5). In these 
mice, the transfected cells could clearly be detected throughout the whole 
cerebellum (Figure 2). These cells were either spherical-shaped or elongated 
(Figure 2A-E). From the injection site, it was possible to detect GFP+ cells 
traveling around the exterior of the cerebellum, in between the lobes, until 
finally penetrating through the molecular layer into the white matter (Figure 
2C-E). Once in the white matter, the cells migrated throughout the whole 
cerebellum. The vast majority of the cells were located in the white matter, 
although a few were found in the various layers of the cerebellar cortex. As 
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for the BMC-treated mice, the majority of the cells were detected outside the 
cerebellum (Figure 2F). These cells were spherical-shaped, and did not seem 
to be capable of penetrating into the cerebellar tissue as seen with MSC.   
Thus, transplanted mesenchymal stem cells, but not whole bone marrow 
cells, are capable of integrating into the cerebellar tissue and migrate 
throughout the cerebellum. 
 
3. Increased number of Purkinje cells in 2 month-old MSC-treated mice 
After the 5 weeks of rotarod assay, control and treated mice were sacrificed, 
perfused and processed by immunohistochemical detection of the injected 
cells, as well as counter-stained with calbindin immunoreactivity to identify the 
Purkinje cells (n=10 in controls, n=8 in sham controls, n=5 in BMC-treated 
mice, and n=10 in MSCs-treated mice). Also, several control mice were 
sacrificed at 1 month of age (n=5). In the 1 month-old control mice, the 
wobbling ataxia of the mouse was very noticeable, and this coincided with a 
low number of Purkinje cells in the cerebellum found in these mice (10-12 
Purkinje cells on average per serial section, see Figure 3A). At 2 months of 
age, this number further decreased to 0-4 Purkinje cells per section (Figure 
3A, B, and E). Similar values were obtained in the sham controls and BM-
treated mice. In the MSC-treated mice, however, at 2 months of age, 
approximately 12 Purkinje cells were detected per section, similar to the 
number found in the mice at 1 month of age (Figure 3A, C and F). As in the 
case of the 1 month-old control mice, the majority of the surviving Purkinje 
cells were located in lobule X. No significant differences were observed in the 
granule layer of both control and experimental groups (Figure 3D and G, 
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respectively). As for the BMC-treated mice, there was no significant increase 
in the number of surviving Purkinje cells compared to the controls. Also, as 
seen at 1 month (Figure 2F), there was practically no presence of bone 
marrow cells in the cerebellum. At this point, the injection sites of both MSCs 
and BMCs mice were practically undetectable except for a few cases.  
As seen in Figure 3A, the number of Purkinje cells per serial section was 
calculated in the 10 sections. Also, the number of mesenchymal stem cells 
per section was calculated and compared to the number of Purkinje cells. As 
a result, we detected 7.5 +/- 3.8 GFP+ cells per surviving Purkinje cell. There 
was very little variability in the number of Purkinje cells detected (124.0 +/- 
18.9), while the number of grafted cells was very variable (418-1918). Thus, 
the number of engrafted cells detected in the cerebellum is not related to the 
number of surviving Purkinje cells.  
Also, although differences in granule cells were not significant, we observed 
an increased immunoreactivity in parvalbumin and GFAP in the molecular 
layer of the treated mice (Figure 3H and J, respectively). Parvalbumin stains 
Purkinje cells as well as basket and stellate cells, which are also affected in 
this mutant mouse, whereas GFAP is a glial marker. Compared to controls 
(Figure 3I and K), treated mice presented a significant increase both cell 
types. 
Our results indicate that MSCs, but not bone marrow cells, support the 
survival of the Purkinje cells detected at 1 month of age, considering the 
similarities both in number and distribution of 1 month-old controls and 2 
month-old treated mice. Also, the grafted cells increased the survival of other 
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cell types in the cerebellum such as basket and stellate interneurons, as well 
as the GFAP immunoreactive glial cells. 
 
4. Mesenchymal stem cells come in contact with dying purkinje cells, avoiding 
their death through neurotrophic factor release 
Two months after the transplant, once the behavior assays have been 
completed, the MSC-treated mice were sacrificed and analyzed (n = 10). In 
this case, the majority of the transplanted cells were not located in the white 
matter, as seen after 1 month. At this moment, the GFP+ cells were generally 
located either throughout the cerebellar parenchyma forming multiple 
branched or spherical structures, or in the Purkinje cell layer (Fig. 3F, 4A). 
Clusters of grafted cells were always localized close or in physical contact 
with the surviving Purkinje cells (Fig. 4B), as well as surrounding blood 
vessels (Fig. 4C). In some mice, it was possible to detect a small fraction of 
GFP+ Purkinje cells with 2 nuclei (Fig. 4D-E), though the percentage of these 
cells was very low compared to the number of GFP+ cells (approximately 1 in 
100 Purkinje cells were GFP+). This indicates a possible cell fusion of the 
transplanted cells with the native Purkinje cells. To further corroborate this 
observation, two months after the transplant, several MSCs-treated mice 
were sacrificed and their cerebella removed for culture (n = 3). The resulting 
cells were cultured in mesenchymal stem cell medium in order to obtain the 
surviving transplanted cells. Initially, it was possible to observe a few GFP+ 
cells floating among the tissue debris, which would eventually adhere to the 
culture dish (Fig. 5A).  The cells were mainly spherical-shaped, and many 
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presented 2 nuclei (Fig. 5B-C). Also, some were calbindin positive. These 
cells did not proliferate in the 7 days the culture was maintained.  
However, cell fusion can not be considered an important cause for the 
increased number of surviving Purkinje cells in the treated mice, as it 
accounts for only 1% of the Purkinje cells, thus other mechanisms must be in 
effect. Since surviving Purkinje cells were mainly localized close to clusters of 
grafted cells, we postulated that the grafted cells were either directly 
expressing or inducing the expression of neurotrophic factors. To this end, 
immunohistochemical analysis of several neurotrophic factors was performed 
(Fig. 6). Of the various neurotrophic factors analyzed, three were expressed 
in the majority of the grafted cells: BDNF, NT-3 and GDNF (Fig. 6A-C, 
respectively). These factors have been previously proven to be involved in 
the survival and proliferation of Purkinje cells (Mount H.T. et al 1994, Mount 
H. et al 1995, Lärkfors L. et al 1996, Tolbert D.L. et al 2003, Chen Q. et al 
2005). The majority of the grafted cells expressed BDNF (56.0% +/- 35.2%), 
while a small fraction expressed NT-3 (7.9% +/- 1.6%) or GDNF (1.1% +/- 
0.9%). Thus, the expression of these factors by the grafted cells may be one 
the main causes for the increase in survival of the Purkinje cells in the treated 
mice. 
  
DISCUSSION 
We have demonstrated that bone marrow-derived mesenchymal stem cells 
avoid Purkinje cell death, as well as molecular layer interneurons and glial cells, 
in a neurodegenerative mouse model of cerebellar ataxia. Since the increase in 
the number of glial cells, basket and stellate neurons coincided with an increase 
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in surviving Purkinje cells, the survival of these cells seem to be the result of 
secondary trophic mechanisms. At least two processes seem to be responsible 
for this neuroprotection: neurotrophic factor release and to a much lesser 
degree cell fusion, without discarding the possibility of mechanical cell-cell 
trophic interactions. Whole bone marrow transplants, on the other hand, were 
not capable of improving the motor functions of the treated mice. Histological 
analysis showed that the cells were not capable of penetrating the cerebellar 
lobes, but rather remained on the outer regions of the cerebellum. 
Mesenchymal stem cells, however, were capable of penetrating into the 
cerebellum and come in contact with the Purkinje cells. In this manner, these 
cells could activate the necessary processes to induce neuroprotection of the 
Purkinje cells. 
It is particularly interesting that mesenchymal stem cells but not whole bone 
marrow transplants induce a significant increase in Purkinje cells. In a previous 
report we observed a selective neurotrophic activity of whole bone marrow cells 
in motorneuron survival using an amyotrophic lateral sclerosis mouse model 
(Cabanes C. et al 2007). This indicates that the neurotrophic potential of a cell 
population for cell therapy in neurodegenerative diseases varies depending on 
the specific neuronal population to rescue. Thus, it is necessary to consider the 
possibility of selecting different cell populations (such as whole bone marrow or 
cultured mesenchymal stem cells) for an efficient neurotrophic effect on specific 
neuronal populations.  
It has been previously shown in various reports that it is possible for cells of 
various origins to fuse with Purkinje neurons (Bae J.S. et al 2005, Bae J.S. et al 
2007, Nygren J.M. et al 2008), although this is the first time to be reported in 
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Lurcher mice. In this model, where Purkinje cells begin to deteriorate at very 
early ages (postnatal day 3-4), we decided to transplant the cells at P0, when 
the cerebellum is still intact and Purkinje cells healthy. The transplanted cells 
were capable of integrating well into the tissue, and by the time the mouse 
reached the age of one month, the stem cells had already extended throughout 
the whole tissue. However, by this time the majority of the Purkinje cells had 
already disappeared. The few surviving neurons seem to be rescued from their 
inevitable death thanks to the mesenchymal stem cells, which can be detected 
throughout the whole tissue, although mainly localized in clusters near surviving 
Purkinje cells. In several cases, cell fusion could be detected by the presence of 
GFP+, calbindin+, double-nucleated Purkinje cells. This was corroborated by 
the extraction and culture of the cerebellum, which resulted in obtaining 
GFP+/calbindin+ cells with 2 nuclei. However, cell fusion accounts for a very 
small percentage of the surviving Purkinje cells, thus other mechanisms must 
be in effect to account for the increased number of neurons in the treated mice. 
Mesenchymal stem cells acting as trophic mediators have been widely studied 
(for a review see Caplan A.I. et al, 2006). We noticed that an important number 
of GFP+ cells did not fuse with Purkinje cells, but rather were located near the 
Purkinje cell layer. The majority of the grafted cells expressed BDNF, whereas a 
small percentage of cells expressed other factors such as NT-3 and GDNF. 
These three neurotrophic factors are implicated in Purkinje cell survival and 
differentiation (Mount H.T. et al 1994, Mount H. et al 1995, Lärkfors L. et al 
1996, Tolbert D.L. et al 2003, Chen Q. et al 2005). 
Despite the low number of Purkinje cells that are rescued, the treated mice 
respond more efficiently in the behavior tests, especially in the constant speed 
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tests. Thus, it is not necessary to recover a large amount of Purkinje neurons in 
order to detect a significant improvement. Also, many of the rescued Purkinje 
neurons were found in lobule X (or the vestibulocerebellum) of the cerebellum, 
which regulates balance and eye movements. This corroborates with the 
improved rotarod results in the treated mice. However, for the mice to improve 
more significantly in this test, it would be necessary to rescue a larger number 
of Purkinje cells. 
In several reports, cell fusion was induced in response to an inflammation or 
injury process (Magrassi L. et al 2007, Johansson C.B. et al 2008). Here, 
besides the injection, there is no induced injury. Thus, no further damage, 
besides the injection of the cells, was necessary to obtain a positive result. 
In conclusion, bone marrow-derived mesenchymal stem cells are capable of 
ameliorating the symptoms of a neurodegenerative disorder such as that found 
in Lurcher mice, by rescuing Purkinje cells from their inevitable death through at 
least cell fusion and neurotrophic factor release, and ultimately improving their 
motor functions, confirming their potential for a possible cellular therapy in 
neurodegenerative diseases.   
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FIGURE LEGENDS. 
 
FIGURE 1. A) Diagram depicting the chronological scheme of the experimental 
procedure. B) Histograms comparing the results of control (black bars), sham 
controls (white bars), bone marrow (BM) treated mice (grey bars), and 
mesenchymal stem cell (MSC) treated mice (blue bars) in the rotarod tests. The 
top histogram presents the seconds the mice were capable of walking before 
falling when the rotarod was placed at a constant speed of 4 rpm, where the 
MSC-treated mice showed a significant improvement beginning on the second 
week (p < 0.05, p < 0.001 with Mann Whitney). The bottom histogram presents 
the maximum speed achieved by the mice when placed in the rotarod at 
increasing speeds (4-40 rpm in regular intervals). In this histogram, the asterisk 
marks the weeks in which the MSC-treated mice had significantly higher values 
than the controls (p < 0.05, p < 0.001 with Mann Whitney). In both histograms, 
the values are presented as mean +/- average deviation. Control mice n=10, 
Sham control mice n=8, BM treated mice n=5, MSC treated mice n=10.  
 
FIGURE 2. Immunohistochemical analysis of the cerebellum in a 1 month-old 
non-symptomatic Lurcher mouse treated with either mesenchymal stem cells 
(A-E) or bone marrow (F). In all images, green is GFP and blue is nuclear DAPI. 
A) Sagittal section taken at 100X demonstrating the presence of spherical-
shaped MSC in the white matter of the treated mice. B) Low-powered sagittal 
image (40X) of the cerebellum in which the injection site was detected as a 
cluster of GFP+ cells (white arrow). Also, additional elongated mesenchymal 
stem cells were detected between the cerebellar lobes (light blue arrow) and 
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penetrating through the molecular layer of one of the lobes and into the white 
matter (red arrow). C) Image of the white arrow in (B), taken at 400X, showing 
the injection site and the cells traveling between the cerebellar lobes. D and E) 
High powered images (630X) of the light blue and red arrows in (B), 
respectively, where it is possible to see the elongated GFP+ cells traveling 
between the cerebellar lobes and through the molecular layer of one of the 
lobes. F) Cerebellar sagittal section of a bone marrow-treated mouse taken at 
40X. In this case, as opposed to the mesenchymal stem cells, the cells 
maintained a spherical shape and very few were detected inside the 
cerebellum. In all the images, PCL marks the Purkinje cell layer, ML the 
molecular layer, WM the white matter, and GL the granular layer. Scale bar 
measures 20 μm in A, 50 μm in B and F, 5 μm in C, and 8 μm in D and E. 
 
FIGURE 3. Number and distribution of Purkinje cells in 1 and 2 month-old 
control and 2 month-old treated mice. A) Histogram presenting the number of 
Purkinje cells detected per sagittal section in 1 month-old controls (Non-TX 
Sympt 1 month, n=5), 2 month-old controls (Non-TX Sympt 2 months, n=10), 2 
month-old sham controls (Sham-TX 2 months, n=8), 2 month-old BM treated 
mice (BM-TX 2 months, n=5) and 2 month-old MSC treated mice (MSC-TX 2 
months, n=10). There was no significant difference among the 2 month-old 
controls, shams and BM-treated mice. However, the number of Purkinje cells in 
the MSC-treated group was significantly higher (p < 0.001). Bars represent 
mean +/- average deviation. B, D, E) Immunohistochemical images of sagittal 
sections of the cerebellum in a 2 month-old symptomatic control mouse (100X 
magnification in (B), 400X in (D) and 40X in (E)). C, F, G) Immunohistochemical 
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images of sagittal sections of the cerebellum in a 2 month-old symptomatic 
MSC treated mouse (100X magnification in (C), 40X in (F) and 400X in (G)). In 
(B-C) and (E-F), Purkinje cells are stained with calbindin in red and DAPI is 
used to stain the nuclei, whereas in (D) and (G), calbindin staining is performed 
with DAB and the tissue counterstained with violet cresyl. In (C), (D) and (G), 
PCL identifies the Purkinje cell layer, ML the molecular layer, WM the white 
matter, and GL the granular layer. H, I) Parvalbumin staining in mesenchymal 
and sham-treated mice, respectively. J, K) GFAP staining in mesenchymal and 
sham-treated mice, respectively. Scale bar measures 20 μm in B and C, 50 μm 
in E and F, 5 μm in D and G-K. 
 
FIGURE 4. Immunohistochemical analysis of the cerebellum of 2-month old 
MSC treated mice. A) Low powered transverse image (40X) of the cerebellum, 
where green GFP+ MSC cells are detected throughout the section. Several 
cells (white arrows), particularly those detected in lobe X, co-express calbindin 
(red), a Purkinje cell marker. B) High powered image (400X) of a sagittal section 
of the cerebellum, in which GFP+ MSC were detected in contact with Purkinje 
cells. C) High powered image (400X) of a sagittal section of the cerebellum, in 
which GFP-positive cells were located surrounding or forming blood vessels. In 
this case, the MSC were also detected nearby or in contact with Purkinje cells. 
(D) High-powered immunohistochemical image (200X) of a GFP and calbindin-
positive Purkinje cell. Blue is nuclear DAPI staining. (E) Close-up image of the 
Purkinje cell in (D), where only the DAPI staining is seen, detecting the 
presence of 2 nuclei in the cell, confirming cell fusion of a grafted mesenchymal 
stem cell with a native Purkinje cell. In this image, the green and white lines 
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delimit the two nuclei present in a single Purkinje cell. In (A-C), PCL identifies 
the Purkinje cell layer, ML the molecular layer, WM the white matter, and GL the 
granular layer. Scale bar measures 50 μm in A, 5 μm in B and C, and 10 μm in 
D. 
 
FIGURE 5. Cell culture of cerebellum extracted from MSC-treated mice. A) 
Phase contrast image of the cerebellar suspension after one day of culture, 
where several GFP-positive cells could be found floating among the debris 
(Image taken at 200X). These cells adhered to the plate after 2-3 days of 
culture. (B-C) Immunocytochemical analysis of the suspension culture after 5 
days. In (B), several GFP-positive cells co-expressed calbindin (in red). C) DAPI 
staining of the image in (B), where it can be seen that several cells presented 2 
nuclei (yellow circles). Scale bar measures 10 μm.   
 
FIGURE 6. Immunohistochemical images of sagittal sections of cerebella of 2 
month-old MSC-treated mice staining for various neurotrophic factors. In all 
cases, green is GFP, red is the neurotrophic factor of interest, and blue is 
nuclear DAPI stain. Under each image, taken at 200X, is an orthogonal section 
of the image, proving that the green and red fluorescence correspond to the 
same cell.  The neurotrophic factors expressed by the grafted cells were A) 
BDNF, B) NT-3 and C) GDNF. In the latter case, GDNF is a neurotrophic factor 
that is mainly detected in the Purkinje cells in the cerebellum, as seen in the 
image (white arrows). In the images, PCL marks the Purkinje cell layer, WM the 
white matter, and GL the granular layer. Scale bar measures 10 μm. 
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